We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 356

Increased scrutiny of drug pricing what should pharmaceutical companies know
  • Baker & Hostetler LLP
  • USA
  • February 2 2016

As U.S. spending on pharmaceuticals continues to rise, reaching $373.9 billion in 2014, government scrutiny of drug pricing practices has increased


Implied Certification and the FCA: Legally False or a False Legality? The Supreme Court Is Set to Decide
  • Baker & Hostetler LLP
  • USA
  • January 29 2016

The United States Supreme Court recently granted certiorari in the case of Universal Health Services, Inc. v. U.S. ex rel. Escobar, No. 15-7, which


10 Tips to Mitigate or Prevent Wage and Hour Litigation in the Post-Acute Industry
  • Baker & Hostetler LLP
  • USA
  • January 29 2016

Wage and hour lawsuits are being filed against employers under federal and state wage and hour laws at a record rate. Most wage and hour claims


As Urged by PhRMA and BIO, Supreme Court Agrees to Review Claim Construction Standard Used in Patent Office Trials
  • Baker & Hostetler LLP
  • USA
  • January 27 2016

Pharmaceutical companies have reason to be pleased with the Supreme Court's recent decision to grant a petition for a writ of certiorari in Cuozzo


Antitrust: “Doctor, Doctor, Give Me the News”
  • Baker & Hostetler LLP
  • USA
  • January 15 2016

Back in April 2015, Teladoc, Inc., which provides U.S. board-certified doctors for consults via phone or online video, filed an antitrust challenge


Federal Circuit denies en banc review of Ariosa v. Sequenom
  • Baker & Hostetler LLP
  • USA
  • December 8 2015

On December 2, 2015, an almost unanimous Federal Circuit decision was issued denying the en banc rehearing of Ariosa v. Sequenom, a case having


CMS finalizes revisions to stark to ease burden on providers, refines “incident to” requirements
  • Baker & Hostetler LLP
  • USA
  • November 20 2015

In its calendar year 2016 Physician Fee Schedule Final Rule published in the Federal Register on November 16, 2015 (Final Rule), the Centers for


Momenta Pharma., Inc. v. Teva Pharma. USA Inc.
  • Baker & Hostetler LLP
  • USA
  • November 19 2015

In Momenta Pharma., Inc. v. Teva Pharma. USA Inc., Nos. 2014-1274, -1277, -1276, and -1278 (Fed. Cir. Nov. 10, 2015) ("Momenta II"), the Federal


Methods of treating a subset of patients are likely nonobvious if the subset exhibits unexpected results
  • Baker & Hostetler LLP
  • USA
  • November 17 2015

In Prometheus Laboratories, Inc. v. Roxane Laboratories, Inc.,1 a recent decision involving methods of treating a specific subset of patients, the


DOJ’s increased scrutiny of pharmaceutical manufacturer and specialty pharmacy ties
  • Baker & Hostetler LLP
  • USA
  • November 11 2015

Over the past two years, the relationship between pharmaceutical manufacturers and specialty pharmacies has been under increased scrutiny by the U.S